mRNA-based personalized cancer vaccines are coming! At LineaRx, Inc., we're driving innovation with our LineaDNA™ and LineaIVT™ based solutions to accelerate the production of the next generation of personalized mRNA therapies through our GMP production of cell-free IVT templates and proprietary LineaRNAP™. Why LineaDNA and LineaIVT? Faster Production - Unlike plasmid-based methods, LineaDNA eliminates the need for bacterial amplification, reducing production timelines. Scalability - Enables efficient, high-yield production of DNA, meeting the growing demand for critical starting materials for personalized mRNA vaccines. Purity and Safety - No unwanted bacterial sequences or antibiotic resistance genes, reducing regulatory concerns and improving vaccine safety. Precision - Designed for seamless in vitro transcription, ensuring optimal mRNA synthesis for robust immune responses. Reduced dsRNA – LineaIVT greatly reduces dsRNA contamination while producing high mRNA yields, improving safety and reducing manufacturing timelines. #CancerImmunotherapy #PersonalizedMedicine #LineaDNA #mRNA #BiotechInnovation #CancerVaccines #AppliedDNA #FutureOfHealthcare #LineaRx #dsRNA https://lnkd.in/eTySB5VM
About us
We have two core business segments, one focused on supply chain authentication across multiple industries. The second is focused on large scale linear DNA production for diagnostics and vaccines.
- Website
-
http://www.adnas.com
External link for Applied DNA Sciences
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Type
- Public Company
- Specialties
- Textile Supply Chain Protection, Cash-In-Transit Protection, Asset Marking, Crime Prevention, large-scale DNA production, authentication technology, Cannabis, Personal Care, Fertilizer, Printing and Packaging, and COVID-19 Solutions
Locations
-
Primary
Get directions
-
Get directions
50 Health Sciences Dr
Stony Brook, New York 11790, US
Employees at Applied DNA Sciences
-
Sanjay M. Hurry
Executive Director, Investor Relations and Corporate Communications, Applied DNA Sciences, Inc. (NASDAQ: APDN)
-
Judy Murrah
President, Chief Operating Officer at Applied DNA Sciences
-
Brian Viscount
Vice President Biopharma and DNA production at Applied DNA Sciences
-
Heather Berry
Updates
-
Applied DNA Clinical Labs (ADCL) has submitted a validation package to the New York State Department of Health (NYSDOH) for our Linea™ Avian Influenza H5 Dx (AIH5 Dx) assay. This PCR-based diagnostic is designed to detect and subtype H5 highly pathogenic avian flu — a pressing threat with growing concern in both animal and human health. Amidst rising cases and urgent CDC advisories, our team remains committed to delivering rapid, reliable solutions for emerging health crises. “Subject to NYSDOH approval, ADCL stands ready to empower physician and patient access to testing nationwide using our existing assets and workflows.” said James Hayward, Ph.D. #MolecularDiagnostics #PublicHealth #AvianInfluenza #H5N1 #PCRTesting #BiotechNews #AppliedDNA #InfectiousDisease #LDT #HealthcareInnovation #EpidemicPreparedness #DiagnosticDevelopment #Genomics #LaboratoryTesting #CLIAcertified https://lnkd.in/eFis9C69
-
We're ready! The 2nd Annual DNA Process Development & Manufacturing Summit starts tomorrow in Boston, MA. Don’t miss our poster presentation, ‘Fast-tracking mRNA Medicines: A synthetic DNA platform to optimize mRNA production’: Tuesday, March 26 at 3:30pm #syntheticbiology #EnzymaticDNAProduction #PCR #mRNA #GeneticMedicine #NucleicAcidBasedTherapies #DNAInnovation #CellFreeDNAProduction #SyntheticDNA #BiotechInnovation
-
-
LineaRx is gearing up to exhibit at the upcoming DNA Process Development & Manufacturing Summit, in Boston, MA starting next Tuesday, March 26. We are excited to showcase our Linea™ IVT and Linea™ DNA platforms. Stop by our booth or visit lineadna.com to learn more! #syntheticbiology #EnzymaticDNAProduction #PCR #mRNA #GeneticMedicine #NucleicAcidBasedTherapies #DNAInnovation #CellFreeDNAProduction #SyntheticDNA #BiotechInnovation
-
-
Applied DNA Sciences announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility within its Stony Brook, NY headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing final testing and is expected to be fully operational by the end of the current month. The Company is actively negotiating a supply agreement for GMP IVT template with a mRNA therapeutic developer. #syntheticbiology #EnzymaticDNAProduction #PCR #mRNA #GeneticMedicine #NucleicAcidBasedTherapies #DNAInnovation #CellFreeDNAProduction #SyntheticDNA #BiotechInnovation
-
LineaRx, Inc. will be attending the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16! Schedule an appointment with Clay Shorrock to learn about how our scalable GMP enzymatic DNA manufacturing services can empower the next generation of genetic medicines. #JPM2025 #mRNA #CancerVaccine #PersonalizedCancerVaccine #vaccine #PersonalizedMedicine
-
-
The State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA’s synthetic DNA, Linea™ DNA, as a critical component in its manufacture. #GeneticMedicines #CAR-T #CARtherapies #syntheticDNA #AML #KnowAML #acutemyeloidleukemia
-
Clay Shorrock and Aaron Chung are all smiles on the final day of the 2024 Personalized Cancer Vaccine Summit in Boston! Contact us to learn more about our scalable biomanufacturing services for personalized DNA/RNA vaccines and therapeutics. #mRNA #CancerVaccine #PersonalizedCancerVaccine #vaccine #PersonalizedMedicine
-
-
LineaRx, Inc. is back in Boston this week at the 2024 Personalized Cancer Vaccine Summit, starting today through December 5. Meet with Clay Shorrock and Aaron Chung to learn about our scalable biomanufacturing services for personalized DNA/RNA vaccines and therapeutics. #mRNA #CancerVaccine #PersonalizedCancerVaccine #vaccine #PersonalizedMedicine
-